Virucidal Activity and Mechanism of Action of Cetylpyridinium Chloride Against SARS-CoV-2

Overview

Journal J Oral Maxillofac Surg Med Pathol

Publisher Elsevier

Specialty Dentistry

Date 2022 Apr 20

PMID 35441076

Authors

Nako Okamoto

Akatsuki Saito

Tamaki Okabayashi

Akihiko Komine

Affiliations

Soon will be listed here.

Abstract

Objective: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen causing the coronavirus disease 2019 (COVID-19) global pandemic. Recent studies have shown the importance of the throat and salivary glands as sites of virus replication and transmission. The viral host receptor, angiotensin-converting enzyme 2 (ACE2), is broadly enriched in epithelial cells of the salivary glands and oral mucosae. Oral care products containing cetylpyridinium chloride (CPC) as a bactericidal ingredient are known to exhibit antiviral activity against SARS-CoV-2 . However, the exact mechanism of action remains unknown.

Methods: This study examined the antiviral activity of CPC against SARS-CoV-2 and its inhibitory effect on the interaction between the viral spike (S) protein and ACE2 using an enzyme-linked immunosorbent assay.

Results: CPC (0.05%, 0.1% and 0.3%) effectively inactivated SARS-CoV-2 within the contact times (20 and 60 s) in directions for use of oral care products . The binding ability of both the S protein and ACE2 were reduced by CPC.

Conclusions: Our results suggest that CPC inhibits the interaction between S protein and ACE2, and thus, reduces infectivity of SARS-CoV-2 and suppresses viral adsorption.

Citing Articles

New Insights Regarding the Use of Relevant Synthetic Compounds in Dentistry.

Dumitrel S, Matichescu A, Dinu S, Buzatu R, Popovici R, Dinu D Molecules. 2024; 29(16).

PMID: 39202881 PMC: 11357206. DOI: 10.3390/molecules29163802.

Comparative evaluation of two cetylpyridinium chloride-based mouthwashes on the mechanical properties and strength loss of elastomeric chains used in dentistry: An vitro study.

Andres Castello C, Zamora-Martinez N, Tarazona-Alvarez B, Paredes-Gallardo V Heliyon. 2024; 10(6):e27721.

PMID: 38545197 PMC: 10965520. DOI: 10.1016/j.heliyon.2024.e27721.

Reduction of SARS-CoV-2 viral load in saliva after rinsing with mouthwashes containing cetylpyridinium chloride: a randomized clinical study.

Bezinelli L, Correa L, Beyerstedt S, Franco M, Rangel E, Benitez C PeerJ. 2023; 11:e15080.

PMID: 38130922 PMC: 10734404. DOI: 10.7717/peerj.15080.

Efficacy of different mouthwashes against COVID-19: A systematic review and network meta-analysis.

Sbricoli L, Schiavon L, Brunello G, Brun P, Becker K, Sivolella S Jpn Dent Sci Rev. 2023; 59:334-356.

PMID: 37854066 PMC: 10579871. DOI: 10.1016/j.jdsr.2023.09.003.

Discovery of PL and M Inhibitors for SARS-CoV-2.

Puhl A, Godoy A, Noske G, Nakamura A, Gawriljuk V, Fernandes R ACS Omega. 2023; 8(25):22603-22612.

PMID: 37387790 PMC: 10275482. DOI: 10.1021/acsomega.3c01110.

References

Munoz-Basagoiti J, Perez-Zsolt D, Leon R, Blanc V, Raich-Regue D, Cano-Sarabia M . Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In Vitro. J Dent Res. 2021; 100(11):1265-1272. DOI: 10.1177/00220345211029269. View

ODonnell V, Thomas D, Stanton R, Maillard J, Murphy R, Jones S . Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection. Function (Oxf). 2020; 1(1):zqaa002. PMC: 7239187. DOI: 10.1093/function/zqaa002. View

Bidra A, Pelletier J, Westover J, Frank S, Brown S, Tessema B . Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse. J Prosthodont. 2020; 29(6):529-533. PMC: 7300649. DOI: 10.1111/jopr.13209. View

Kratzel A, Todt D, Vkovski P, Steiner S, Gultom M, Thao T . Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 by WHO-Recommended Hand Rub Formulations and Alcohols. Emerg Infect Dis. 2020; 26(7):1592-1595. PMC: 7323537. DOI: 10.3201/eid2607.200915. View

Busscher H, White D, Atema-Smit J, Geertsema-Doornbusch G, de Vries J, van der Mei H . Surfactive and antibacterial activity of cetylpyridinium chloride formulations in vitro and in vivo. J Clin Periodontol. 2008; 35(6):547-54. DOI: 10.1111/j.1600-051X.2008.01230.x. View

Bordbar A, Taheri-Kafrani A, Mousavi S, Haertle T . Energetics of the interactions of human serum albumin with cationic surfactant. Arch Biochem Biophys. 2007; 470(2):103-10. DOI: 10.1016/j.abb.2007.11.015. View

Otzen D . Protein-surfactant interactions: a tale of many states. Biochim Biophys Acta. 2011; 1814(5):562-91. DOI: 10.1016/j.bbapap.2011.03.003. View

Lachapelle J . A comparison of the irritant and allergenic properties of antiseptics. Eur J Dermatol. 2014; 24(1):3-9. DOI: 10.1684/ejd.2013.2198. View

Popkin D, Zilka S, Dimaano M, Fujioka H, Rackley C, Salata R . Cetylpyridinium Chloride (CPC) Exhibits Potent, Rapid Activity Against Influenza Viruses and . Pathog Immun. 2017; 2(2):252-269. PMC: 5605151. DOI: 10.20411/pai.v2i2.200. View

10.

Vergara-Buenaventura A, Castro-Ruiz C . Use of mouthwashes against COVID-19 in dentistry. Br J Oral Maxillofac Surg. 2020; 58(8):924-927. PMC: 7428696. DOI: 10.1016/j.bjoms.2020.08.016. View

11.

Fernandes L, Pacheco V, Borges L, Athwal H, de Paula Eduardo F, Bezinelli L . Saliva in the Diagnosis of COVID-19: A Review and New Research Directions. J Dent Res. 2020; 99(13):1435-1443. DOI: 10.1177/0022034520960070. View

12.

Seneviratne C, Balan P, Ko K, Udawatte N, Lai D, Ng D . Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore. Infection. 2020; 49(2):305-311. PMC: 7734110. DOI: 10.1007/s15010-020-01563-9. View

13.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

14.

Mukherjee P, Esper F, Buchheit K, Arters K, Adkins I, Ghannoum M . Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections. BMC Infect Dis. 2017; 17(1):74. PMC: 5237564. DOI: 10.1186/s12879-016-2177-8. View

15.

Herrera D, Serrano J, Roldan S, Sanz M . Is the oral cavity relevant in SARS-CoV-2 pandemic?. Clin Oral Investig. 2020; 24(8):2925-2930. PMC: 7309196. DOI: 10.1007/s00784-020-03413-2. View

16.

Koch-Heier J, Hoffmann H, Schindler M, Lussi A, Planz O . Inactivation of SARS-CoV-2 through Treatment with the Mouth Rinsing Solutions ViruProX and BacterX Pro. Microorganisms. 2021; 9(3). PMC: 8002120. DOI: 10.3390/microorganisms9030521. View

17.

Eduardo F, Correa L, Heller D, Daep C, Benitez C, Malheiros Z . Salivary SARS-CoV-2 load reduction with mouthwash use: A randomized pilot clinical trial. Heliyon. 2021; 7(6):e07346. PMC: 8222261. DOI: 10.1016/j.heliyon.2021.e07346. View

18.

Amin M, Sorour M, Kasry A . Comparing the Binding Interactions in the Receptor Binding Domains of SARS-CoV-2 and SARS-CoV. J Phys Chem Lett. 2020; 11(12):4897-4900. DOI: 10.1021/acs.jpclett.0c01064. View

19.

Martinez Lamas L, Diz Dios P, Perez Rodriguez M, Perez V, Cabrera Alvargonzalez J, Lopez Dominguez A . Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo tests. Oral Dis. 2020; 28 Suppl 1:908-911. PMC: 7362147. DOI: 10.1111/odi.13526. View

20.

Wolfel R, Corman V, Guggemos W, Seilmaier M, Zange S, Muller M . Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581(7809):465-469. DOI: 10.1038/s41586-020-2196-x. View